FEN EP is a clinical-stage medical device company, developing a disruptive diagnostic solution to predict treatment options to prevent Sudden Cardiac Death (SCD). The Company’s patented cardiac device uses electrophysiological methods and data-driven software analytics to predict patients’ medical needs for an Implantable Cardioverter Defibrillator (ICD). FEN EP requires £1.4m in investment to enable an exit by trade sale within 5 years.